IL161989A0 - Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure - Google Patents
Use of norepinephrine reuptake inhibitors for the treatment of cognitive failureInfo
- Publication number
- IL161989A0 IL161989A0 IL16198902A IL16198902A IL161989A0 IL 161989 A0 IL161989 A0 IL 161989A0 IL 16198902 A IL16198902 A IL 16198902A IL 16198902 A IL16198902 A IL 16198902A IL 161989 A0 IL161989 A0 IL 161989A0
- Authority
- IL
- Israel
- Prior art keywords
- treatment
- reuptake inhibitors
- norepinephrine reuptake
- cognitive failure
- cognitive
- Prior art date
Links
- 230000001149 cognitive effect Effects 0.000 title 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 title 1
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33917401P | 2001-12-11 | 2001-12-11 | |
| PCT/US2002/036132 WO2003049724A1 (en) | 2001-12-11 | 2002-11-27 | Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL161989A0 true IL161989A0 (en) | 2005-11-20 |
Family
ID=23327833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL16198902A IL161989A0 (en) | 2001-12-11 | 2002-11-27 | Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20050009925A1 (https=) |
| EP (1) | EP1458368B1 (https=) |
| JP (1) | JP2005517647A (https=) |
| KR (1) | KR20040066895A (https=) |
| CN (1) | CN1713900A (https=) |
| AU (1) | AU2002352625A1 (https=) |
| BR (1) | BR0213581A (https=) |
| CA (1) | CA2467802A1 (https=) |
| CO (1) | CO5590907A2 (https=) |
| CZ (1) | CZ2004709A3 (https=) |
| DE (1) | DE60223718T2 (https=) |
| EA (1) | EA200400793A1 (https=) |
| EC (1) | ECSP045145A (https=) |
| ES (1) | ES2295435T3 (https=) |
| HR (1) | HRPK20040528B3 (https=) |
| HU (1) | HUP0402619A3 (https=) |
| IL (1) | IL161989A0 (https=) |
| MX (1) | MXPA04005716A (https=) |
| MY (1) | MY136367A (https=) |
| NO (1) | NO20042904L (https=) |
| NZ (1) | NZ532065A (https=) |
| PL (1) | PL369311A1 (https=) |
| SK (1) | SK2442004A3 (https=) |
| TW (1) | TW200300672A (https=) |
| WO (1) | WO2003049724A1 (https=) |
| ZA (1) | ZA200404274B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1530476A1 (en) * | 2002-08-14 | 2005-05-18 | Pharmacia & Upjohn Company LLC | Use of reboxetine for the treatment of hot flashes |
| EP1708717B1 (en) * | 2003-07-28 | 2011-10-05 | Leslie Joe Dunaway | Atomoxetine for treatment of allergic rhinitis and asthma |
| EP1660064A2 (en) * | 2003-08-27 | 2006-05-31 | Eli Lilly And Company | Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors |
| EP1729754B1 (en) * | 2003-12-12 | 2008-07-02 | Eli Lilly And Company | Selective norepinephrine reuptake inhibitors for the treatment of hot flashes |
| BRPI0510453A (pt) * | 2004-04-30 | 2007-10-30 | Warner Lambert Co | composto substituìdos com morfolina para o tratamento de distúrbios do sistema nervoso central |
| US7439399B2 (en) * | 2004-06-28 | 2008-10-21 | Teva Pharmaceutical Fine Chemicals | Processes for the preparation of atomoxetine hydrochloride |
| US8580776B2 (en) * | 2007-07-10 | 2013-11-12 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for treating neurodegenerating diseases |
| US20100069389A1 (en) * | 2008-09-06 | 2010-03-18 | Bionevia Pharmaceuticals, Inc. | Novel forms of reboxetine |
| US20100317730A1 (en) * | 2009-06-12 | 2010-12-16 | Shaya Elias K | Treatment for menopausal and perimenopausal vasomotor symptons |
| WO2011014475A2 (en) * | 2009-07-31 | 2011-02-03 | National Taiwan University | Treating negative symptoms of schizophrenia associated with defective neuregulin 1 |
| JP6126531B2 (ja) * | 2011-10-03 | 2017-05-10 | 国立研究開発法人国立長寿医療研究センター | タウ凝集阻害剤 |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
| US9907799B2 (en) | 2013-04-02 | 2018-03-06 | The Doshisha | Tau aggregation inhibitor |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4314081A (en) * | 1974-01-10 | 1982-02-02 | Eli Lilly And Company | Arloxyphenylpropylamines |
| US5281624A (en) * | 1991-09-27 | 1994-01-25 | Eli Lilly And Company | N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof |
| US5658590A (en) * | 1995-01-11 | 1997-08-19 | Eli Lilly And Company | Treatment of attention-deficit/hyperactivity disorder |
| US6465458B1 (en) * | 1999-07-01 | 2002-10-15 | Pharmacia & Upjohn Company | Method of treating or preventing chronic pain with a highly selective norepinephrine reuptake inhibitor |
| AP2002002481A0 (en) * | 1999-10-13 | 2002-06-30 | Pfizer Prod Inc | Biaryl ether derivatives useful as monoamine reuptake inhibitors. |
| AU2002243451A1 (en) * | 2001-01-02 | 2002-07-16 | Sention, Inc. | Use of catecholamine reuptake inhibitors to enhance memory |
| JP2004517112A (ja) * | 2001-01-02 | 2004-06-10 | ファルマシア・アンド・アップジョン・カンパニー | 新規薬物コンビネーション |
-
2002
- 2002-11-27 BR BR0213581-7A patent/BR0213581A/pt not_active IP Right Cessation
- 2002-11-27 WO PCT/US2002/036132 patent/WO2003049724A1/en not_active Ceased
- 2002-11-27 IL IL16198902A patent/IL161989A0/xx unknown
- 2002-11-27 EA EA200400793A patent/EA200400793A1/ru unknown
- 2002-11-27 AU AU2002352625A patent/AU2002352625A1/en not_active Abandoned
- 2002-11-27 NZ NZ532065A patent/NZ532065A/en unknown
- 2002-11-27 CZ CZ2004709A patent/CZ2004709A3/cs unknown
- 2002-11-27 ES ES02789574T patent/ES2295435T3/es not_active Expired - Lifetime
- 2002-11-27 JP JP2003550773A patent/JP2005517647A/ja active Pending
- 2002-11-27 CA CA002467802A patent/CA2467802A1/en not_active Abandoned
- 2002-11-27 KR KR10-2004-7009039A patent/KR20040066895A/ko not_active Withdrawn
- 2002-11-27 SK SK244-2004A patent/SK2442004A3/sk not_active Application Discontinuation
- 2002-11-27 DE DE60223718T patent/DE60223718T2/de not_active Expired - Fee Related
- 2002-11-27 CN CNA028247264A patent/CN1713900A/zh active Pending
- 2002-11-27 HU HU0402619A patent/HUP0402619A3/hu unknown
- 2002-11-27 HR HR20040528A patent/HRPK20040528B3/xx not_active IP Right Cessation
- 2002-11-27 EP EP02789574A patent/EP1458368B1/en not_active Expired - Lifetime
- 2002-11-27 US US10/496,765 patent/US20050009925A1/en not_active Abandoned
- 2002-11-27 MX MXPA04005716A patent/MXPA04005716A/es not_active Application Discontinuation
- 2002-11-27 PL PL02369311A patent/PL369311A1/xx unknown
- 2002-12-05 TW TW091135296A patent/TW200300672A/zh unknown
- 2002-12-05 MY MYPI20024591A patent/MY136367A/en unknown
-
2004
- 2004-05-31 ZA ZA200404274A patent/ZA200404274B/en unknown
- 2004-06-09 CO CO04054292A patent/CO5590907A2/es not_active Application Discontinuation
- 2004-06-09 EC EC2004005145A patent/ECSP045145A/es unknown
- 2004-07-09 NO NO20042904A patent/NO20042904L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BR0213581A (pt) | 2004-08-24 |
| CA2467802A1 (en) | 2003-06-19 |
| DE60223718D1 (de) | 2008-01-03 |
| US20050009925A1 (en) | 2005-01-13 |
| ECSP045145A (es) | 2004-07-23 |
| KR20040066895A (ko) | 2004-07-27 |
| DE60223718T2 (de) | 2008-10-30 |
| ZA200404274B (en) | 2005-09-13 |
| HRPK20040528B3 (en) | 2006-03-31 |
| CZ2004709A3 (cs) | 2004-10-13 |
| AU2002352625A1 (en) | 2003-06-23 |
| EP1458368A1 (en) | 2004-09-22 |
| HUP0402619A2 (hu) | 2005-03-29 |
| TW200300672A (en) | 2003-06-16 |
| JP2005517647A (ja) | 2005-06-16 |
| SK2442004A3 (en) | 2004-12-01 |
| MXPA04005716A (es) | 2004-12-06 |
| CO5590907A2 (es) | 2005-12-30 |
| WO2003049724A1 (en) | 2003-06-19 |
| NO20042904L (no) | 2004-09-07 |
| EP1458368B1 (en) | 2007-11-21 |
| ES2295435T3 (es) | 2008-04-16 |
| EA200400793A1 (ru) | 2004-10-28 |
| NZ532065A (en) | 2007-03-30 |
| HRP20040528A2 (en) | 2004-10-31 |
| CN1713900A (zh) | 2005-12-28 |
| PL369311A1 (en) | 2005-04-18 |
| HUP0402619A3 (en) | 2008-04-28 |
| MY136367A (en) | 2008-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL373568A1 (en) | Use of i kappa b kinase inhibitors for the treatment of pain | |
| NO20035609D0 (no) | Fremgangsmåte for kontinuerlig naftabehandling | |
| IL159347A0 (en) | Arylamines for the treatment of conditions associated with gsk-3 | |
| IL159344A0 (en) | Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease | |
| PL369895A1 (en) | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease | |
| NO20014047D0 (no) | Monoamin reopptaksinhibitorer for behandling av CNS forstyrrelser | |
| IL160187A0 (en) | Aerosolized decongestants for the treatment of sinusitis | |
| WO2004047830A3 (de) | Pharmazeutische zusammensetzung aus einem beta-3-adrenozeptor-agonisten und einem serotonin- und/oder norepinephrin-reuptake-inhibitor deren verwendung zur behandlung von blasenfunktionsstörungen | |
| IL209319A0 (en) | Substituted tetracycline compounds for the treatment of malaria | |
| IL162485A0 (en) | Compounds for the treatment of inflammatory disorders | |
| SI1448205T1 (sl) | Kombinacije za zdravljenje imunoinflamatornih motenj | |
| IL161989A0 (en) | Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure | |
| AU2002360437A8 (en) | Reducing myelin-mediated inhibition of axon regeneration | |
| IL157145A0 (en) | Use of dc23 antagonists for the treatment of neoplastic disorders | |
| PL377552A1 (pl) | Leczenie zespołu nadpobudliwości psychoruchowej z deficytem uwagi | |
| PT2314627T (pt) | Método para o tratamento de esclerose múltipla | |
| IL162308A0 (en) | Aminoindane derivatives as serotonin and norepinephrine uptakeinhibitors | |
| EP1461030A4 (en) | AMINOALKYL-BENZOFURAN-5-OL COMPOUNDS FOR THE TREATMENT OF GLAUCOMA | |
| IL162818A0 (en) | Combination therapy for the treatment of bacterialinfections | |
| IL161748A0 (en) | New use for the treatment of gastroesophageal reflux | |
| PT1530462E (pt) | Compostos 1-fenil-2-dimetilaminometilciclo-hexano utilizados na terapia dos sintomas depressivos, dor e incontinência | |
| AU2002249947A1 (en) | Inhibition of protein-phosphatases for the treatment of heart failure | |
| HK1069540A (en) | Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure | |
| GB2410744B (en) | Kinase inhibitors for the treatment of disease | |
| AU2003227521A1 (en) | Combination of atypical antipsychotic and serotonin reuptake inhibitor for the treatment of chronic pain |